In a significant leadership shift within America’s top public health institutions, Jay Bhattacharya has been named acting director of the Centers for Disease Control and Prevention while continuing to serve as director of the National Institutes of Health. The move places a well known and sometimes controversial figure at the helm of two of the nation’s most influential health agencies.
This development comes during a time of shifting public trust, ongoing policy debates, and evolving public health priorities in the United States. Here is a detailed look at what this leadership change means, the background behind it, and what could come next for the CDC and NIH.
Dr. Bhattacharya, a former Stanford University physician and economist, has temporarily stepped into the top role at the CDC following the departure of Jim O'Neill, who is moving on to lead the National Science Foundation.
While continuing his responsibilities at the NIH, Bhattacharya will oversee the CDC’s public health initiatives, vaccine advisory committees, and disease response strategies. The appointment is temporary, as the White House continues to search for a permanent CDC director who must receive confirmation from the U.S. Senate.
This dual leadership role is unusual and places Bhattacharya in a powerful position to influence federal public health research and policy at the same time.
Jay Bhattacharya first became widely known during the COVID 19 pandemic. He co authored the "Great Barrington Declaration," a document that questioned nationwide lockdowns and school closures. The declaration argued that pandemic response policies should focus primarily on protecting vulnerable populations, especially older adults, rather than implementing widespread restrictions across society.
His views often placed him at odds with public health leaders who supported broader mitigation strategies such as masking mandates, school shutdowns, and social distancing measures.
In 2024, Bhattacharya publicly criticized the CDC’s pandemic response, writing that the agency had promoted what he described as flawed science during a national crisis. He specifically challenged claims regarding the effectiveness of widespread masking policies.
These statements have continued to shape how both supporters and critics view his leadership style and public health philosophy.
Bhattacharya assumes this role at a time when trust in the CDC has experienced fluctuations. According to a recent poll by the Kaiser Family Foundation, public trust in the agency declined from nearly 60 percent in early 2025 to 47 percent more recently.
Rebuilding confidence in public health institutions is likely to be one of the central challenges of his tenure. Public trust plays a critical role in vaccine uptake, compliance with health guidance, and cooperation during disease outbreaks.
The CDC is responsible for issuing guidance on infectious diseases, vaccination schedules, and emergency responses. Any shift in tone or policy direction could have broad implications for both healthcare professionals and the general public.
One of the most closely watched areas under Bhattacharya’s leadership will be vaccine recommendations. As acting CDC director, he will oversee the committee responsible for issuing vaccine guidance in the United States.
While Bhattacharya has been a strong critic of vaccine mandates, he has clearly distinguished that position from opposition to vaccines themselves. During a U.S. Senate hearing earlier this month, he stated that vaccinating children against measles is the best way to address measles outbreaks in the country.
This nuanced position could shape how future vaccine policies are communicated. Rather than focusing on mandates, the emphasis may shift toward individual choice combined with strong scientific messaging about vaccine benefits.
Given ongoing measles cases and concerns about declining childhood vaccination rates, this area will likely remain a top priority.
Reports indicate that Bhattacharya’s immediate goal is to stabilize the CDC, which has faced internal disagreements over policy and direction in recent years.
The agency has experienced significant scrutiny since the COVID 19 pandemic, with debates surrounding lockdowns, school closures, masking recommendations, and evolving scientific guidance.
Bhattacharya has argued that some pandemic policies lacked sufficient evidence to justify their broader social and economic consequences. He has pointed to the unintended effects of school closures and prolonged restrictions on children and families.
Whether his leadership style will unify the agency or deepen divisions remains to be seen.
Leading both the CDC and NIH places Bhattacharya in a unique position within the federal health system. The NIH focuses primarily on biomedical research and funding scientific studies, while the CDC translates research findings into public health guidance and disease control strategies.
Holding both roles simultaneously may create opportunities for stronger coordination between research and policy implementation. However, it also raises questions about workload, oversight, and governance.
The NIH funds billions of dollars in research annually, covering everything from cancer treatments to infectious disease studies. Meanwhile, the CDC is responsible for frontline public health responses, disease surveillance, and emergency preparedness.
Balancing these responsibilities will require careful management and clear communication.
Public health leadership appointments often carry political implications. Bhattacharya’s previous criticisms of federal health policies make his appointment especially notable.
Supporters argue that his perspective brings needed reform and transparency to federal health agencies. Critics worry that past disagreements over pandemic strategies could influence future disease response policies.
As the White House continues its search for a permanent CDC director, Bhattacharya’s tenure could shape the agency’s direction for years to come, even if his role remains temporary.
The coming months will likely focus on several key areas:
Public health agencies operate under intense scrutiny, especially in a post pandemic environment. Transparent communication, evidence based policymaking, and consistent messaging will be essential.
The Washington Post, February 18, 2026.
This article is for informational and educational purposes only. It summarizes publicly reported news regarding federal health leadership and does not constitute medical, legal, or professional advice. Statistical data cited reflect general trends and may not apply to individual circumstances. Public health policies and leadership roles may change over time. Always consult qualified healthcare professionals for personal medical decisions.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.